SKB 518
Alternative Names: SKB-518Latest Information Update: 10 Mar 2026
At a glance
- Originator Sichuan Kelun Pharmaceutical Research Institute
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA polymerase I inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Lung cancer
- Phase I/II Solid tumours
Most Recent Events
- 04 Mar 2026 Sichuan Kelun Pharmaceutical Research Institute plans a phase-II trial for Ovarian cancer, Cervical cancer and Endometrial cancer (Monotherapy, Combination Therapy, Late-stage disease, Second-line therapy or greater) in China (Parenteral, Injection), (NCT07448922)
- 08 Sep 2025 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in China (IV) (Sichuan Kelun Pharmaceutical Research Institute pipeline; September 2025)
- 29 Aug 2025 Phase-II clinical trials in Lung cancer in China (IV) (NCT07019675)